Epidermal Expression of Host Response Genes upon Skin Barrier Disruption in Normal Skin and Uninvolved Skin of Psoriasis and Atopic Dermatitis Patients  by de Koning, Heleen D. et al.
Epidermal Expression of Host Response Genes upon Skin
Barrier Disruption in Normal Skin and Uninvolved Skin
of Psoriasis and Atopic Dermatitis Patients
Journal of Investigative Dermatology (2011) 131, 263–266; doi:10.1038/jid.2010.278; published online 23 September 2010
TO THE EDITOR
Recent studies have identified genetic
risk factors for atopic dermatitis (AD)
and psoriasis that may affect skin
barrier function (Palmer et al., 2006;
de Cid et al., 2009). Deficiencies in skin
barrier formation or dysfunctional re-
pair will expose epidermal cells to
environmental stimuli, such as micro-
bial components, which could evoke
an inflammatory response, shaped by
the genetic background of the host.
These genetic studies, the demonstra-
tion of cell-autonomous differences
between normal and patient keratino-
cytes (Zeeuwen et al., 2008), and the
distinct antimicrobial protein (AMP)
expression profiles in psoriasis and AD
lesional skin (Ong et al., 2002; de Jongh
et al., 2005) prompted us to investigate
the responses of patients and controls to
skin barrier disruption. We examined
the effect of tape stripping and SDS-
induced irritant contact dermatitis
(Supplementary Materials and Methods
online) on the expression of host
defense genes in uninvolved epider-
mis of psoriasis and AD patients and
healthy controls.
AMP gene expression levels were
upregulated in all conditions of skin
barrier disruption and subject groups,
whereas expression profiles of pattern
recognition receptors and inflamma-
some-related signaling genes were only
marginally affected by barrier disrup-
tion, irrespective of the subject group
(Table 1, Supplementary Tables 1 and 2
online, Supplementary Figure 1 online).
As cytokines control the expression
of AMPs, we analyzed the response of
several psoriasis- and AD-associated
cytokines on skin barrier disruption.
However, no significant differences
in expression of Th1, Th2, and Th17
cytokines were found (not shown). The
sole significant difference between
normal and patient skin was down-
regulation of Toll-like receptor-3 in
non-lesional skin of psoriasis and AD
patients. Caspase-1 was the only gene
that showed significant differential ex-
pression between the barrier disruption
models (twofold higher expression in
SDS-treated skin). At the protein level,
AMP expression was strongly induced
48 hours after skin barrier disruption
(Figure 1). Protein expression was rather
similar in the different conditions of
barrier disruption, even though there
seemed to be a tendency toward
stronger staining in the SDS-treated
samples.
Interestingly, experimental barrier
disruption induced similar high AMP
levels in non-lesional skin of both
psoriasis and AD patients, whereas in
(untreated) lesional skin, these levels
are much higher in psoriasis (Ong et al.,
2002; de Jongh et al., 2005). Possibly,
lesional cytokine levels account for the
latter, as the AD-specific Th2 cytokines
IL-4 and IL-13 were found to down-
regulate AMP expression in keratino-
cytes (Nomura et al., 2003; Albanesi
et al., 2007). This is a likely scenario
in vivo, as IL-4 and IL-13 were only
expressed in purified epidermal sheets
of AD lesions and not in tape-stripped
non-lesional skin of AD patients (not
shown). We therefore examined the
effect of Th2 cytokine addition on Th1
cytokine-induced AMP expression in
cultured primary keratinocytes from
healthy subjects and patients with
psoriasis and AD. Cells were stimulated
with IFN-g, tumor necrosis factor-a
and IL-1a (referred to as Th1 cytokines),
Th2 cytokines (IL-4 and IL-13), or
both. Indeed, Th2 cytokines caused
significant suppression of the Th1-
mediated induction of DEFB4, DEF-
B103A, PI3, and SLPI in all groups
(Supplementary Figure 2a online, Sup-
plementary Table 3 online). Moreover,
several AMPs were expressed at sig-
nificantly lower levels in AD patient-
derived keratinocytes compared with
both healthy and psoriasis patient-de-
rived keratinocytes on stimulation with
both Th1 and Th2 cytokines (Supple-
mentary Figure 2 online, Supplemen-
tary Table 4 online). At the protein
level, Th1-mediated induction of hBD-
2, but not elafin, was significantly
suppressed by Th2 cytokines (Supple-
mentary Figure 2b online, Supplemen-
tary Table 3 online). Stimulation by a
combination of Th1 and Th2 cytokines
resulted in upregulation of Toll-like
receptor-3 in keratinocytes from psor-
iasis and AD patients, which was
significant compared with intra-indivi-
dual unstimulated samples, but not
compared with healthy subjects (Sup-
plementary Tables 3 and 4 online).
Previously, induction of psoriasin,
hBD-2, hBD-3, and RNase 7 protein
was reported after tape stripping of
normal skin (Glaser et al., 2009; Harder
et al., 2010), which is in line with our
results. Our study shows that skin
barrier disruption, either mechanically
induced or through irritant contact
dermatitis, elicits a striking increase in
mRNA and protein expression levels
of many AMPs, whereas the expres-
sion levels of pattern recognition recep-
tors and some inflammasome-related
signaling molecules were largely
unaltered. Interestingly, almost all exa-
mined host defense gene expression
levels were similarly influenced by
barrier disruption in healthy skin and
non-lesional skin of psoriasis or AD
patients. This proves that non-lesional
AD patient epidermis is equallyAbbreviations: AD, atopic dermatitis; AMP, antimicrobial protein
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Table 1. Relative epidermal mRNA expression levels of host defense genes after SDS application or tape stripping
Fold change1 P-value compared with US2
HUGO gene symbol Synonym SDS3 TS NS4 TS PS5 TS AD6 SDS TS NS TS PS TS AD
Toll-like receptors
TLR2 1.1 0.6 0.7 0.8 0.921 0.019 0.077 0.147
TLR3 0.6 0.4 0.1 0.2 0.028 0.003 o0.001 o0.001
TLR5 0.6 0.9 0.8 0.9 0.203 0.309 0.139 0.262
C-type lectins
CLEC2B CLECSF2 6.8 3.3 2.7 2.2 0.001 0.013 0.152 0.348
CLEC7A Dectin-1 1.4 1.6 2.3 2.0 0.679 0.204 0.003 0.028
Nucleotide-binding oligomerization domain-like receptors
NLRP1 NALP1 0.3 0.4 0.6 0.4 0.007 0.006 0.020 0.005
NLRP2 NALP2 3.3 1.3 0.4 0.3 0.577 0.062 0.053 0.014
NOD1 CARD4 0.6 0.9 2.3 1.3 0.020 0.357 0.053 0.364
NOD2 CARD15 1.1 5.7 6.8 4.9 0.742 0.316 0.006 0.016
RIG-like helicases
DDX58 RIG-I 1.6 0.9 2.6 1.7 0.305 0.373 0.311 0.131
IFIH1 MDA5 1.6 1.9 4.1 3.1 0.008 0.223 0.097 0.030
Diverse
RIPK2 RIP2 1.2 1.2 1.9 2.0 0.463 0.166 0.180 0.045
PYCARD ASC 2.7 3.0 1.6 2.1 0.006 0.012 0.310 0.054
ICEBERG Caspase-1 inhibitor 0.8 0.4 0.4 1.3 0.286 0.058 0.005 0.989
CASP1 ICE 1.6 0.8 0.7 1.2 0.056 0.103 0.004 0.650
IL1RN IL-1RA 2.5 2.7 2.3 3.3 0.748 0.465 0.196 0.061
IL1A IL-1a 4.9 1.1 2.3 9.6 0.634 0.705 0.267 0.420
IL1B IL-1b 8.3 1.8 9.2 2.4 0.191 0.932 0.047 0.119
IL18 IL-18 1.2 2.0 0.8 0.7 0.033 0.391 0.281 0.049
Antimicrobial peptides
DEFB4 hBD-2 1,901 21,760 9,394 9,359 o0.001 0.001 0.001 0.002
DEFB103A hBD-3 12 43 43 41 0.025 0.010 0.032 0.003
PI3 Elafin 368 597 780 627 o0.001 o0.001 o0.001 o0.001
S100A7 Psoriasin 120 113 77 136 o0.001 0.002 o0.001 o0.001
S100A8 MRP8 941 333 139 655 0.001 o0.001 o0.001 o0.001
S100A9 MRP14 1,548 2,018 781 1,739 o0.001 o0.001 o0.001 o0.001
SLPI SLPI 6.3 5.8 3.2 4.8 0.004 o0.001 0.004 o0.001
LYZ Lysozyme 7.9 3.1 2.6 7.4 0.052 0.031 0.004 0.052
CAMP LL37 15 123 357 85 0.091 o0.001 0.001 0.001
Abbreviation: RIG, retinoid acid inducible gene.
1Relative epidermal mRNA expression levels calculated by taking the mean of the treated samples each divided by the relative mRNA expression level of its
intra-individual control sample as calculated by Livak’s delta–delta quantitative PCR cycle times method.
2P-value of dCt of treated samples compared with intra-individual control samples of untreated skin (US). Shaded: upregulated more than 10 times. Bold:
P-value of analysis of variance and Bonferroni post hoc test below 0.05.
3Mean ratio in SDS-treated skin.
4Tape-stripped healthy normal skin (TS NS).
5Tape-stripped non-lesional skin of psoriasis patients (TS PS).
6Tape-stripped non-lesional skin of atopic dermatitis patients (TS AD).
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capable of producing massive amounts
of AMPs on skin barrier perturbation as
psoriasis patient epidermis. This is
remarkable in view of the lower AMP
levels in cultured keratinocytes from
AD patients, either or not stimulated
with Th1 or Th2 cytokines (Zeeuwen
et al., 2008) or both cytokine mixtures
(this study). Previous studies showed
that, depending on the specific AMP,
these molecules are expressed at equal
or higher levels in lesional AD skin than
in normal skin, but these expression
levels are exceeded considerably by
those in lesional psoriasis skin (de Jongh
et al., 2005; Gambichler et al., 2008;
Ballardini et al., 2009; Harder et al.,
2010). Apart from cell-autonomous
(genetically programmed) low AMP
expression levels in lesional AD
keratinocytes, the particular local cyto-
kine environment (Th1/Th17 versus Th2)
may also be involved, as demonstrated
by the Th2-mediated partial inhibition of
Th1-induced AMP expression in kerati-
nocytes from healthy subjects and pa-
tients with AD and psoriasis.
Altogether, our data show that enhan-
ced expression levels of epidermal
















Figure 1. Protein expression of psoriasin, MRP8, elafin, and hBD-2 after SDS application or tape stripping of human skin. Immunohistochemical staining of
normal skin, and skin 48 hours after barrier disruption by means of either SDS application of normal skin, or tape stripping of normal skin (TS NS) or uninvolved
skin of psoriasis (TS PS) and atopic dermatitis (TS AD) patients. Treated skin was compared with intra-individual healthy control skin. Each picture is
representative of data from six different individuals; the healthy controls, from 24 different individuals. Bar¼100 mm.
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disruption, irrespective of the genetic
predisposition of the keratinocytes
(normal, psoriasis, or AD background).
This phenomenon may possibly depend
on the massive damage-induced release
of preformed cytosolic stimuli, such as
IL-1a. Modifying factors such as genetic
programming (for example, filaggrin or
LCE3B/C deficiency, differential sensi-
tivity to cytokines) and cytokine envir-
onment could have a role in the repair
process, which may be qualitatively
different in psoriasis and AD. Contin-
ued barrier deficiency will stimulate the
production of factors that induce in-
flammation and recruitment of immune
cells, eventually including Th1/Th17
cells in psoriasis and mainly Th2 cells
in AD. This process will also determine
epidermal host defense gene expres-
sion levels: a full-blown antimicrobial
defense in psoriasis or a dampened
antimicrobial response that promotes
skin colonization and superinfection as
observed in AD.
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TO THE EDITOR
Sphingosine-1-phosphate (S1P) is a
unique lipid in that on the one hand it
is part of the lipid fraction securing the
epidermal permeability barrier and on
the other hand, it has been shown to act
as a critical signaling molecule and to
elicit a variety of partially contrasting
cellular effects. The significance of S1P
in immune cell regulation became
obvious when it was discovered that
the novel immunosuppressive drug
FTY720 (fingolimod) causes lymphope-
nia via S1P signaling (Mandala et al.,
2002). In skin, sphingosine can be
cleaved from ceramides, which account
for 30–40% of stratum corneum lipids
(Herzinger et al., 2007). Sphingosine
can then be phosphorylated by sphingo-
sine kinases to S1P, which binds to a
family of G-protein-coupled receptors,
termed S1P1–S1P5. S1P signaling is
irreversibly inactivated by an S1P lyase.Abbreviation: S1P, sphingosine-1-phosphate
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